

If you are a private investor, you should not act or rely on this document but should contact your professional advisor.

ECONOMIC AND FUND REVIEW

Most of the major global equity markets suffered in April as investors feared a deteriorating economic outlook affecting companies' prospects. Fixed income markets also declined, as inflation concerns remained firmly on the agenda during the month. US consumer price inflation hit a new high of 8.5% in April. Investors were increasingly concerned that this round of central bank tightening will be faster than previous cycles. The US Federal Reserve (Fed) reaffirmed this with a series of comments that spoke to the need for controlling inflation. Subsequently, expectations for rate hikes increased dramatically, causing government bond yields to move higher and prices to drop.

Meanwhile, China continued pursuing its zero-Covid strategy. In an effort to contain cases of the Omicron variant, it imposed a strict lockdown in Shanghai at the end of March. The disruption led to food shortages, extreme congestion at Shanghai's large trade port and logistical difficulties transporting goods. This situation, coupled with fears that it may be repeated elsewhere in China, added to concerns over supply chain challenges and inflation.

Colgate contributed positively to returns, proving its worth as a defensive consumer staple with a reliable revenue stream. As inflation concerns in most markets will likely put pressure on consumers' appetite for discretionary items, demand for toothpaste products should remain relatively steady. The fund also benefitted from its holding in US pharmaceutical company Merck. The group reported better than expected earnings thanks to their main cancer drug, Keytruda, and their Covid drug, Molnupiravir.

Detractors from performance included Daikin, which was affected by fears over the slowing property sector in China. Investors are worried about the way further lockdowns may impact building development. The US broadband cable provider Charter Communications also detracted from performance. Their earnings indicated that that competition from telecoms providers was impacting growth.

We started a position in Thermo Fisher, the world's largest life sciences tools company with a long track record of growth. Their products and services address many of the world's problems linked to ageing populations. They also work closely in innovative biopharma projects. In order to fund this purchase, we reduced our position in the pharmaceutical company Amgen.

OUTLOOK

The ongoing Russia-Ukraine conflict and the outlook for inflation are among the key concerns for investors. In addition, the impact of lockdowns in China is increasingly being felt on a global scale. The long-term effects of sanctions and rising oil prices due to the war in Eastern Europe will only be known in the months ahead. In the short term, we expect market volatility to remain heightened.

Looking out to the longer term: the invasion of Ukraine has come at a difficult time for the global economy. In the aftermath of the pandemic, prices are already rising at levels not seen in 40 years. In addition, Russia is one of the world's largest gas producers and energy prices have been rising sharply as a result. In short, the impact on price levels could become a unique challenge for global central banks. If allowed to persist, it could raise the risk of stagflation. The crisis is also likely to depress growth, sustain uncertainty and damage consumer and business confidence.

The fragmentation of global supply chains and cross-border trade may also be further exacerbated. In particular: China's 'dynamic clearance' policy – which requires testing and quarantine for positive Covid-19 cases – is of great concern. It has already led to city shutdowns and can add further supply chain disruption. For global manufacturers though, these are yet more reasons to shorten supply chains, bolster domestic production facilities and sacrifice margins in return for security of supply.

As events are changing with remarkable speed, we continue to monitor risks to the outlook. We remain focused on high-quality assets that we believe are well positioned to withstand the implications of geopolitical events.

Beyond the conflict in Ukraine, there are other challenges that require close monitoring. Rising inequality must be tackled, while the climate crisis is an unprecedented threat to humanity. Corporations and investors have a role to play in both instances, seeking to support innovation and development through effective allocation of capital.

Despite the challenges, we remain focused on the opportunities inevitably provided during times of great upheaval. Ultimately, the reaction function of central banks to inflation and economic data is likely to be the defining factor for asset markets over the next 12 months.



IMPORTANT INFORMATION

If you are a private investor, you should not act or rely on this document but should contact your professional advisor.

This promotion has been approved by Sarasin & Partners LLP of Juxon House, 100 St Paul's Churchyard, London, EC4M 8BU, a limited liability partnership registered in England & Wales with registered number OC329859 which is authorised and regulated by the Financial Conduct Authority with firm reference number 475111.

The investments of the fund are subject to normal market fluctuations. **The value of the investments of the fund and the income from them can fall as well as rise and investors may not get back the amount originally invested.** If investing in foreign currencies, the return in the investor's reference currency may increase or decrease as a result of currency fluctuations. **Past performance is not a guide to future returns and may not be repeated.**

There is no minimum investment period, though we would recommend that you view your investment as a medium to long term one (i.e. 5 to 10 years). Frequent political and social unrest in Emerging Markets, and the high inflation and interest rates this tends to encourage, may lead to sharp swings in foreign currency markets and stock markets. There is also an inherent risk in the smaller size of many Emerging Markets, especially since this means restricted liquidity. Further risks to bear in mind are restrictions on foreigners making currency transactions or investments. For efficient portfolio management the Fund may invest in derivatives. The value of these investments may fluctuate significantly, but the overall intention of the use of derivative techniques is to reduce volatility of returns.

All details in this document are provided for marketing and information purposes only and should not be misinterpreted as investment advice or taxation advice. This document is not an offer or recommendation to buy or sell shares in the fund. You should not act or rely on this document but should seek independent advice and verification in relation to its contents. Neither Sarasin & Partners LLP nor any other member of the Bank J. Safra Sarasin group accepts any liability or responsibility whatsoever for any consequential loss of any kind arising out of the use of this document or any part of its contents. The views expressed in this document are those of Sarasin & Partners LLP and these are subject to change without notice.

This document does not explain all the risks involved in investing in the fund and therefore you should ensure that you read the prospectus and the Key Investor Information document which contain further information including the applicable risk warnings. The prospectus, the Key Investor Information document as well as the annual and semi-annual reports are available free of charge from www.sarasinandpartners.com or from Sarasin & Partners LLP, Juxon House, 100 St Paul's Churchyard, London, EC4M 8BU, Telephone +44 (0)20 7038 7000, Telefax +44 (0)20 7038 6850. Telephone calls may be recorded.

Where the data in this document comes partially from third party sources the accuracy, completeness or correctness of the information contained in this publication is not guaranteed, and third-party data is provided without any warranties of any kind. Sarasin & Partners LLP shall have no liability in connection with third party data.

Persons who are domiciled in the USA or are US nationals are not permitted to hold shares in the fund and shares may not be publicly sold, offered or issued to anyone residing in the USA or to US nationals. This publication is intended for investors in the United Kingdom.

© 2022 Sarasin & Partners LLP – all rights reserved. This document can only be distributed or reproduced with permission from Sarasin & Partners LLP. Please contact marketing@sarasin.co.uk.

SARASIN & PARTNERS LLP

Juxon House, 100 St. Paul's Churchyard
London EC4M 8BU

T +44 (0)20 7038 7037

www.sarasinandpartners.com

